Roche Diagnostics hereby submits this Special $5 1 0 ( \mathrm { k } )$ to provide notification of modification to our Total Bilirubin Spccial test system. The reagent was originally cleared for use as:

COBAS INTEGRA Total Bilirubin Special K981632/A001 And modified as COBAS INTEGRA Total Bilirubin Special K063543

Modifications to the test systems include:

• Reagent application to the cobas c 111 analyzer • Other editorial labeling changes

A full description of the diffcrences and similarities between performance of Total Bilirubin Special on the COBAS INTEGRA 400 plus and cobas c 111 is described bclow.

The cobas c 11 1 analyzer is a new member of the COBAS INTEGRA $\textsuperscript { \textregistered }$ family of analyzers and will usc reagents and calibrators identical to those of other INTEGRA analyzers. The cobas c I 11 is a device modification of the current COBAS INTEGRA $\textcircled{1}$ 400 plus analyzer, cleared in a letter to file K95 1595. A full description of the differcnces and similarities between the two analyzers, software modifications and a summary of the design validation and verification activities for the modified software is included in this submission as part of the modifications to the Total Bilirubin Special test system.

In accordance with the FDA policy, new applications of previously cleared reagents to the cobas c 11 1 analyzer werc completed, along with new labeling in the form of cobas c I 1 1 package inserts. For all subsequent applications of previously cleared reagents, Roche Diagnostics is following the FDA guidance, Replacement Reagent and Instrument Family Policy  Dec 11, 2003, to demonstrate equivalence to the original reagent/instrument performance. Data will be available for FDA review upon request.

The additional labeling provided in this submission is for purposes of CLIA categorization.

# Device Name

# Proprietary name: Total Bilirubin Special

Classification name: Bilirubin (total or dircct) test system

# Establishment Registration

The establishment registration number for Roche Diagnostics Gmbh Penzberg is 9610529.

The establishment registration number for Roche Diagnostics Corporation is 1823260.

The establishment registration number for Roche instrument Center (RIC) is 3003795116.

# Classification

The FDA has classified a discrete photometric chemistry analyzer in Class I.

<table><tr><td>Panel</td><td>Classification Number</td><td>Classification Name</td><td>Regulation Citation</td></tr><tr><td>75 Clinical Chemistry</td><td>CIG</td><td>Bilirubin (total or direct) test system</td><td>21 CFR 862.111 0</td></tr></table>

# Device Description

The Total Bilirubin Special reagent is intended for use on the cobas c 111 analyzer for the quantitative determination of total or direct bilirubin in serum and plasma.

The cobas c 111 analyzer is a partially automated, in-vitro diagnostic analyzer capable of performing clinical chemistry, specific protein and electrolyte tests. Analytes are measured photometrically or turbidimetrically; the analyzer also has an optional ISE module for measuring sodium, potassium and chloride.

The cobas c 111 instrument is a random access analyzer designed to be operated on a bench top in the professional environment using a combination of a photomeri analysisunit and anoptionalion selectiveelectrodes (ISE).

# Performance Standards

# Intended use

# Predicate device

The table below indicates the similarities and differences between the modified Bilirubin total reagent and its predicate device.

Substantial equivalencySimilarities   

<table><tr><td colspan="1" rowspan="1">Feature</td><td colspan="1" rowspan="1">Modified Device:Total Bilirubin Special</td><td colspan="1" rowspan="1">Predicate device:COBAS INTEGRA Total BilirubinSpecial, K063543</td></tr><tr><td colspan="3" rowspan="1">General</td></tr><tr><td colspan="1" rowspan="1">Intended Use/Indications forUse</td><td colspan="1" rowspan="1">In vitro test for the quantitativedetermination of total bilirubin inhuman serum and plasma on thecobas c 111 system.</td><td colspan="1" rowspan="1">The COBAS INTEGRA TotalBilirubin Special (BILTS) cassettecontains an in vitro diagnosticreagent system intended for use onCOBAS INTEGRA systems for thequantitative determination of totalbilirubin in serum and plasma ofadults and neonates (test BILTS, 0-985).</td></tr><tr><td colspan="1" rowspan="1">Specimen</td><td colspan="1" rowspan="1">serum and plasma</td><td colspan="1" rowspan="1">serum and plasma</td></tr><tr><td colspan="3" rowspan="1">Test Principle</td></tr><tr><td colspan="1" rowspan="1">Referencemethod</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Diazo method</td></tr><tr><td colspan="3" rowspan="1">Reagent information</td></tr><tr><td colspan="1" rowspan="1">Reagentcomposition</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">R1: Sodium acetate buffer 85mmol/L, Sulfamic acid 110 mmol/LR2: Hydrochloric acid 100 mmol/L,Diazonium ion 3 mmol/L</td></tr><tr><td colspan="1" rowspan="1">Stability - shelflife and on-board</td><td colspan="1" rowspan="1">2-8 °C until expiration dateOn-board 4 weeks</td><td colspan="1" rowspan="1">2-8 °C until expiration dateCOBAS INTEGRA 400/400 plus:On-board at 10-15 C 5 weeksCOBAS INTEGRA 700/800:On-board at 8 C 5 weeks</td></tr><tr><td colspan="1" rowspan="1"></td><td></td><td></td></tr><tr><td colspan="1" rowspan="1">Calibrator</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Calibrator f.a.s.</td></tr><tr><td colspan="1" rowspan="1">Quality control</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Precinorm U, Precipath UPrecinorm U plus, Precipath U plus</td></tr><tr><td colspan="1" rowspan="1">Traccability</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Standardized against the Doumasreference method</td></tr><tr><td colspan="2" rowspan="1">Performance characteristics</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Precision</td><td colspan="1" rowspan="1">Within-run1.79% @ 21.7 μmol/L0.64% @ 64.2 μmol/1.2.94% @ 15.2 μmol/L0.77% @ 60.0 μmol/LTotal2.32% @ 21.6 µmol/L0.71% @ 67.4 μmol/L3.10% @ 16.2 µmol/L0.79% @ 83.0 μmol/L</td><td colspan="1" rowspan="1">Within run:2.44% @ 15.80 μmol/L1.39% @ 54.00 μmol/LBetween day:4.13% @ 14.7 μmol/L2.15% @ 47.20 µmol/L</td></tr><tr><td colspan="1" rowspan="1">Measuringrange</td><td colspan="1" rowspan="1">0.1-25.2 mg/dL0.1-101 mg/dL (with postdilution)</td><td colspan="1" rowspan="1">0-25 mg/dL0-250 mg/dL (with postdilution)</td></tr><tr><td colspan="1" rowspan="1">Lower detectionlimit</td><td colspan="1" rowspan="1">0.1 mg/dL</td><td colspan="1" rowspan="1">0.063 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Expected values(literaturcreferencc</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Adults and children: up to 1.0mg/dLNeonates:Age of newborn Premature24hrs: 1.0-6.0 mg/dL48hrs: 6.0-8.0 mg/dL3-5 days: 10.0-15.0 mg/dLAge of newborn Full Term24hrs: 2.0-6.0 mg/dL48hrs: 6.0-7.0 mg/dL3-5 days: 4.0-12.0 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Endogenousinterferences</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Hemolysis: No significantinterference up to 1000 mg/dLLipemia: No significant interferenceup to 1400 mg/dL as Intralipid</td></tr><tr><td colspan="2" rowspan="1">Exogenousinterferences</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Ascorbic acid at 30 mg/dL causesartificially decreased total bilirubinvalues</td></tr><tr><td colspan="4" rowspan="1">Analyzer</td></tr><tr><td colspan="2" rowspan="1">Topic</td><td colspan="1" rowspan="1">cobas c 111 Analyzer(Modified Device)</td><td colspan="1" rowspan="1">COBAS INTEGRA® 400 pluswith ISE(K951595)</td></tr><tr><td colspan="4" rowspan="1">Analyzer Description</td></tr><tr><td colspan="2" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">The Roche cobas c 111 analyzer isan in-vitro diagnostic analyzercapable of performing clinicalchemistry, specific protein andelectrolyte tests. Analytes aremeasured photometrically orturbidimetrically; thc analyzer alsohas an optional ISE module formeasuring sodium, potassium andchloride.</td><td colspan="1" rowspan="1">The Roche COBAS INTEGRA 400plus is an automated in vitrodiagnostic analyzer capable ofperforming general chemistry,specific protein, electrolyte tests,therapeutic drug, drug of abuse andthyroid analyses. It is equipped withmodules for absorption photometry,fluorescence polarizationphotometry and potentiometry (ISE)and works in conjunction with invitro diagnostic reagents.</td></tr><tr><td colspan="2" rowspan="1">Analyzer Description (continued)</td><td colspan="2" rowspan="1">Analyzer Description (continued)</td></tr><tr><td colspan="2" rowspan="1">Measurementprinciple</td><td colspan="1" rowspan="1">•Absorbancc Photometry(enzymes, substrates,proteins)ISE Potentiometry(electrolytes)</td><td colspan="1" rowspan="1">Absorbance Photometry(enzymes, substrates,proteins, DAT)Fluorescence Photometry(TDM)ISE Potentiometry(electrolytes)</td></tr><tr><td colspan="1" rowspan="1">Reactionmodes</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Endpoint, kinetic, potentiometric</td></tr><tr><td colspan="4" rowspan="1">Software SIMILARITIES</td></tr><tr><td colspan="2" rowspan="1">Software</td><td colspan="1" rowspan="1">cobas c 111 analyzer software</td><td colspan="1" rowspan="1">Cobas Integra® 400 plus AnalyzerSoftware</td></tr><tr><td colspan="2" rowspan="1">Configuration</td><td colspan="1" rowspan="1">Integrated bench top analyzer(including Absorbance Photometer)with optional ISE unit</td><td colspan="1" rowspan="1">Integrated benchtop analyzer (incl.Abs, FP-Photometer &amp; ISE module)</td></tr><tr><td colspan="2" rowspan="1">Functionsperformed</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Data input, sample processing, resultcalculation, result reporting, qualitycontrol</td></tr><tr><td colspan="2" rowspan="1"></td><td></td><td></td></tr><tr><td colspan="1" rowspan="1">ComputerInfrastructure</td><td colspan="1" rowspan="1">Data management &amp; user interactionon cmbedded CPU with Linuxoperating analyzerInstrument management and real-time control on cmbedded CPU withvxWorks opcrating analyzer</td><td colspan="1" rowspan="1">Data management &amp; user interactionon PC based computer withWindows XP operating analyzerInstrument management and real-timc control on embedded CPU withvxWorks operating analyzer</td></tr><tr><td colspan="1" rowspan="1">AnalyticalFunctions</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Control of analytical processes(pipetting, incubation, detection),primary signal processing</td></tr><tr><td colspan="1" rowspan="1">Data storage</td><td colspan="1" rowspan="1">Same but no patient demographicsare stored (due to less storagecapacity).</td><td colspan="1" rowspan="1">Storage of analyzer and applicationparameters, calibration data, QCdata, sample results, alarms, patientdemographics, service actions andstatus information</td></tr><tr><td colspan="1" rowspan="1">Resultcalculation</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Automated measuring of signal forkinetic and cndpoint methodsaccording to cycle time andautomated calculation ofconcentration via calibration curve</td></tr><tr><td colspan="1" rowspan="1">Usermanagement</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">User ID and password</td></tr><tr><td colspan="1" rowspan="1">Flagging oferrors</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Available</td></tr><tr><td colspan="2" rowspan="1">Software DIFFERENCES</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Initial cassettevolume check(ICVC) forreagentpipetting</td><td colspan="1" rowspan="1">Not applicable:Instead of cassettes single bottleswith liquid levcl detection are used</td><td colspan="1" rowspan="1">Available</td></tr><tr><td colspan="1" rowspan="1">Data concept(Applicationparametertransfer</td><td colspan="1" rowspan="1">Applications via barcode</td><td colspan="1" rowspan="1">Applications via diskette</td></tr><tr><td colspan="1" rowspan="1">Data concept(Cal/QCassigned values)</td><td colspan="1" rowspan="1">Automatic QC when QC samplesare placed manually</td><td colspan="1" rowspan="1">Automatic QC with on board QCsamples</td></tr><tr><td colspan="3" rowspan="1">Analyzer Features</td></tr><tr><td colspan="1" rowspan="1">Throughput</td><td colspan="1" rowspan="1">Max 100 tests per hour</td><td colspan="1" rowspan="1">Max 400 tests per hour</td></tr><tr><td colspan="1" rowspan="1">Analyzer Size</td><td colspan="1" rowspan="1">Same but smaller</td><td colspan="1" rowspan="1">Integrated benchtop analyzer</td></tr><tr><td colspan="1" rowspan="1">Sample Handling</td><td></td><td></td></tr><tr><td colspan="1" rowspan="1">Typical samplevolumes</td><td colspan="1" rowspan="1">Typically 2 - 10 µ1, pcr test (same)ISE (serum, plasma):25 μL (indirect mode)ISE (urine):25 μL (indirect mode):</td><td colspan="1" rowspan="1">Typically 2 - 10 µL per testISE (serum, plasma):20 μL (indirect mode)97 μL (direct mode)ISE (urine):20 μL (indirect mode):</td></tr><tr><td colspan="1" rowspan="1">Sample Types</td><td colspan="1" rowspan="1">Same, but not CSF</td><td colspan="1" rowspan="1">Serum, plasma, urine, CSF;whole blood and hemolysate forHbA1c</td></tr><tr><td colspan="1" rowspan="1">SampleHandlingAnalyzer</td><td colspan="1" rowspan="1">Sample area for samples, calibratorsand controls.</td><td colspan="1" rowspan="1">Rack analyzer for samples,calibrators and controls.</td></tr><tr><td colspan="1" rowspan="1">Sample capacityon board</td><td colspan="1" rowspan="1">8 places for cups / tubes.</td><td colspan="1" rowspan="1">Up to six racks with max. 15 samplecups/tubes per rack on board.</td></tr><tr><td colspan="1" rowspan="1">Sampleidentification</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">1D- Barcode</td></tr><tr><td colspan="3" rowspan="1">Reagent Handling</td></tr><tr><td colspan="1" rowspan="1">ReagentVolume</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">20-150 μL</td></tr><tr><td colspan="1" rowspan="1">ReagentContainer</td><td colspan="1" rowspan="1">Unisys 20mL bottle</td><td colspan="1" rowspan="1">Integra cassette / cobas c pack</td></tr><tr><td colspan="1" rowspan="1">ReagentContainer(Electrolytes)</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Plastic bottles closed with screwcaps</td></tr><tr><td colspan="1" rowspan="1">Reagent Access</td><td colspan="1" rowspan="1">Manual opening of bottle prior toplacement on board</td><td colspan="1" rowspan="1">Reagent cassette caps piercedautomatically inside the instrument.</td></tr><tr><td colspan="1" rowspan="1">Onboardstoragetemperature</td><td colspan="1" rowspan="1">Refrigerated 6-10 °C (43-50 °F)</td><td colspan="1" rowspan="1">Refrigerated 10 - 15 °C (50-59 °F)</td></tr><tr><td colspan="1" rowspan="1">Reagentbottle/cassetteidentification</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Barcode</td></tr><tr><td colspan="1" rowspan="1">On boardreagent storagecapacity</td><td colspan="1" rowspan="1">27 reagent bottles</td><td colspan="1" rowspan="1">32 cassettes</td></tr><tr><td colspan="1" rowspan="1">Analyzer cycletime</td><td colspan="1" rowspan="1">18 sec</td><td colspan="1" rowspan="1">10.6 sec</td></tr><tr><td colspan="1" rowspan="1">Reagent mixing</td><td colspan="1" rowspan="1">Stirring in cuvette with stcel probe</td><td colspan="1" rowspan="1">Integrated cuvette vortex mixer</td></tr><tr><td colspan="1" rowspan="1">Auto rerun</td><td colspan="1" rowspan="1">Manual only</td><td colspan="1" rowspan="1">Available</td></tr><tr><td colspan="3" rowspan="1">Pipetting Analyzer</td></tr><tr><td colspan="1" rowspan="1">Sample andreagent syringes</td><td colspan="1" rowspan="1">XZ-Phi robotic syringe</td><td colspan="1" rowspan="1">XYZ robotic syringe</td></tr><tr><td colspan="1" rowspan="1">Reagent probes</td><td colspan="1" rowspan="1">1 polished steel probe with modifieddesign (used for sample &amp; reagent)</td><td colspan="1" rowspan="1">2 polished steel probes (used forsample &amp; reagent)</td></tr><tr><td colspan="1" rowspan="1">Sample probes</td><td colspan="1" rowspan="1">1 polished stecl probe with modifieddesign (used for sample &amp; reagent)</td><td colspan="1" rowspan="1">2 polished steel probes (used forsample &amp; reagent)</td></tr><tr><td colspan="1" rowspan="1">Probe cleaning</td><td colspan="1" rowspan="1">Samc</td><td colspan="1" rowspan="1">Automatic incl. carry over evasion</td></tr><tr><td colspan="1" rowspan="1">Liquid leveldetection</td><td colspan="1" rowspan="1">Same (+ reagent pipetting)</td><td colspan="1" rowspan="1">Both probes conductance for samplepipetting</td></tr><tr><td colspan="1" rowspan="1">Clot detection</td><td colspan="1" rowspan="1">Not available</td><td colspan="1" rowspan="1">Available - pressure sensor</td></tr><tr><td colspan="3" rowspan="1">Test Reaction Chamber</td></tr><tr><td colspan="1" rowspan="1">TemperatureControl</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Heated air bath 37 °C (99 °F)</td></tr><tr><td colspan="1" rowspan="1">Cuvettes</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">PMMA acrylic plastic - for singleuse</td></tr><tr><td colspan="3" rowspan="1">ISE Module</td></tr><tr><td colspan="1" rowspan="1">ISE Module</td><td colspan="1" rowspan="1">Serum, plasma indirect (1:6 dilution)Urine indircct (1:6 dilution)One-point calibration evcry samplemeasurement.</td><td colspan="1" rowspan="1">Serum, plasma direct (undiluted)Serum, plasma indirect (1:6 dilution)Urine indirect (1:6 dilution)One-point calibration every samplemeasurement.</td></tr><tr><td colspan="1" rowspan="1">Ion SelectiveElectrodes</td><td colspan="1" rowspan="1">Same but no lithium electrode</td><td colspan="1" rowspan="1">Potentiometric: chloride, potassium,sodium, lithium and referenceelectrode</td></tr><tr><td colspan="1" rowspan="1">ISE throughput</td><td colspan="1" rowspan="1">60 samples / h</td><td colspan="1" rowspan="1">66 samples / h</td></tr><tr><td colspan="2" rowspan="1">Detection Information</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Spectrophotometer</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Grating monochromator and diodearray</td></tr><tr><td colspan="1" rowspan="1">Light source</td><td colspan="1" rowspan="1">Tungsten / Halogen lamp, 20 W</td><td colspan="1" rowspan="1">Tungsten / Halogen lamp, 100 W</td></tr><tr><td colspan="1" rowspan="1">Light path</td><td colspan="1" rowspan="1">Samc</td><td colspan="1" rowspan="1">5 mm path length</td></tr><tr><td colspan="1" rowspan="1">Measuring unit</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Intensity (0 - 2.0 A)</td></tr><tr><td colspan="1" rowspan="1">Wavelengths</td><td colspan="1" rowspan="1">340, 378, 409, 449, 480, 512,520, 552, 583, 629, 652, 659 nmmono- and bichromaticmeasurements</td><td colspan="1" rowspan="1">340, 378, 409, 480, 512, 520,552, 583, 629, 652, 659, 800 nmmono- and bichromaticmeasurements</td></tr><tr><td colspan="1" rowspan="1">Calibration and quality control</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Calibrators</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Multiple use</td></tr><tr><td colspan="1" rowspan="1">Calibrationmodes</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Linear, non linear. Multiplestandards. Generation of multipointstandard curves by automaticdilution.</td></tr><tr><td colspan="1" rowspan="1">Calibration / onboard stability</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Typically each lot or 12 weeks forsame reagent on board</td></tr><tr><td colspan="1" rowspan="1">Control storageon instrument</td><td colspan="1" rowspan="1">To be placed on demand</td><td colspan="1" rowspan="1">Within sample area possible</td></tr><tr><td colspan="1" rowspan="1">Calibrator /control valuetransfer</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Via barcode transfer sheet or manualentry</td></tr><tr><td colspan="1" rowspan="1">Internal qualitymanagementanalyzer</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Available to monitor and validatetest results</td></tr><tr><td colspan="3" rowspan="1">Interfaces</td></tr><tr><td colspan="1" rowspan="1">Host interface</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">RS232C bi-directional</td></tr></table>

Proposed Labeling   

<table><tr><td rowspan=1 colspan=1>Printer</td><td rowspan=1 colspan=1>Internal thermo paper printer</td><td rowspan=1 colspan=1>Standalone LaserJet type</td></tr><tr><td rowspan=1 colspan=1>Display</td><td rowspan=1 colspan=1>Internal LCD touch panel ( 1/4 VGAsize)</td><td rowspan=1 colspan=1>Standalone 17&quot; computer display w.keyboard and mouse</td></tr></table>

Total Bilirubin Special reagent:

Proposed labcling sufficient to describe the device, its intended use, and the dircctions for use can be found in the separately attached document. We believe the proposed version of the device labeling presented contains all of the technical information required per 21 CFR 809.10.

cobas c 111 analyzer:   
Draft cobas cl 1 1 method manual shccts and example cassette labels for CLIA categorization purposes in this submission.

A complete User's Manual for thc cobas cl 11 analyzer is provided in Volume II of this submission.

A CD-ROM containing the COBAS INTEGRA 400 plus Operator's Manual (the predicate device for cobas c I 1 1 analyzer) is included with this submission.

We believe thc proposed version of the device labeling presented contains al of the technical information required pcr 21 CFR 809.10.

# Validation and Design Control

Development activities were conducted under appropriate design control procedures and the ovcrall product specifications were met. The Results of Risk Analysis and Declaration of Conformity with Design Controls are provided with this submission.

# Confidentiality

Roche Diagnostics requests that the FDA not disclose the nature or existence of this submission until the substantial equivalence decision has been reached.

# Closing

Modification of the Bilirubin Total reagent does not affect the intended use or indications for use of the devicc as described in the labeling, nor does it alter the fundamental scicntific technology of the device. Therefore, we trust the information provided in this Spccial 5 10(k) will support a decision of substantial cquivalence to its predicate for the Total Bilirubin Special application to cobas c 1 1 1 analyzer.

An clectronic copy (scanned pdf version) of this submission can be provided upon request. If you have any questions or require further information, please do not hesitate to contact this office.

Phone: (317) 521-3831 • FAX: (317) 521-2324 email: corina.harperar roche.com

Sincerely,

Corina Harper, RAC Regulatory Affairs Consultant Roche Diagnostics Corporation

Roche Diagnostics 9115 Hague Road Indianapolis, IN 46250 Attn: Corina Harper

# JAN 17 2007

Re: k063744 Trade/Device Name: Total Bilirubin Special Regulation Number: 21 CFR $\ S 8 6 2 . 1 1 1 0$ Regulation Name: Bilirubin (total or direct) test system. Regulatory Class: Class II Product Code: CIG Dated: December 15, 2006 Received: December 18, 2006

Dear Ms. Harper:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with al the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

This letter will allow you to begin marketing your device as described in your Section $5 1 0 ( \mathrm { k } ) \dot { }$ prearket notiicaton.The DA findin o substantial equivalence o yourdevice o a lally markete predicate device results in a classification or your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0490. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address at   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Jean M.Coopes, M.S. D.V.M. Yean M. Cooper, M.S., D.V.M.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and   
Radiological Health

# Indications for Use

510(k) Number (if known): K063744

Device Name:

Total Bilirubin Special

Indications For Use:

In vitro test for the quantitative determination of total bilirubin in human serum and plasma on the cobas c 111 system.

Measurements of the levels of bilirubin and organic compound formed during normal and abnormal destruction of red cells, is used in the diagnosis of liver, hemolytic hematological and metabolic disorders, including hepatitis and gall bladder block.

Prescription Use __XXX_ AND/OR Over-The-Counter Use (Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Page 1 of 1

Office of In Vitro Diagnostic Device Evaluation and Safety $N a 6 3 7 4 4$